Comparative network analysis revealed that the ME/CFS epigenetic signature shares key molecular nodes (e.g., IL-2, IL-10, CD4) with immunomodulatory therapies such as Rituximab and Copaxone, which have shown promise in ME/CFS treatment [41, 50]. Here, CD4 is linked to myalgic encephalomeyelitis/chronic fatigue syndrome.